IBDEI0JN ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19799,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,19799,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,19799,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,19800,0)
 ;;=D56.0^^86^994^21
 ;;^UTILITY(U,$J,358.3,19800,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19800,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,19800,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,19800,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,19801,0)
 ;;=D63.1^^86^994^23
 ;;^UTILITY(U,$J,358.3,19801,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19801,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,19801,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,19801,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,19802,0)
 ;;=D63.0^^86^994^24
 ;;^UTILITY(U,$J,358.3,19802,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19802,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,19802,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,19802,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,19803,0)
 ;;=D63.8^^86^994^22
 ;;^UTILITY(U,$J,358.3,19803,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19803,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,19803,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,19803,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,19804,0)
 ;;=C22.3^^86^994^26
 ;;^UTILITY(U,$J,358.3,19804,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19804,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,19804,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,19804,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,19805,0)
 ;;=D61.9^^86^994^27
 ;;^UTILITY(U,$J,358.3,19805,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19805,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,19805,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,19805,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,19806,0)
 ;;=D56.1^^86^994^29
 ;;^UTILITY(U,$J,358.3,19806,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19806,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,19806,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,19806,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,19807,0)
 ;;=C83.79^^86^994^31
 ;;^UTILITY(U,$J,358.3,19807,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19807,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,19807,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,19807,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,19808,0)
 ;;=C83.70^^86^994^32
 ;;^UTILITY(U,$J,358.3,19808,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19808,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,19808,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,19808,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,19809,0)
 ;;=D09.0^^86^994^39
 ;;^UTILITY(U,$J,358.3,19809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19809,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,19809,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,19809,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,19810,0)
 ;;=D06.9^^86^994^40
 ;;^UTILITY(U,$J,358.3,19810,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19810,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,19810,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,19810,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,19811,0)
 ;;=D06.0^^86^994^42
 ;;^UTILITY(U,$J,358.3,19811,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19811,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,19811,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,19811,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,19812,0)
 ;;=D06.1^^86^994^43
 ;;^UTILITY(U,$J,358.3,19812,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19812,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,19812,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,19812,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,19813,0)
 ;;=D06.7^^86^994^41
 ;;^UTILITY(U,$J,358.3,19813,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19813,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,19813,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,19813,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,19814,0)
 ;;=D04.9^^86^994^44
 ;;^UTILITY(U,$J,358.3,19814,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19814,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,19814,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,19814,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,19815,0)
 ;;=C91.11^^86^994^47
 ;;^UTILITY(U,$J,358.3,19815,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19815,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,19815,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,19815,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,19816,0)
 ;;=C91.10^^86^994^48
 ;;^UTILITY(U,$J,358.3,19816,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19816,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,19816,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,19816,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,19817,0)
 ;;=C92.11^^86^994^49
 ;;^UTILITY(U,$J,358.3,19817,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19817,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,19817,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,19817,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,19818,0)
 ;;=C92.10^^86^994^50
 ;;^UTILITY(U,$J,358.3,19818,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19818,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,19818,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,19818,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,19819,0)
 ;;=D47.1^^86^994^51
 ;;^UTILITY(U,$J,358.3,19819,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19819,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,19819,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,19819,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,19820,0)
 ;;=C82.69^^86^994^52
 ;;^UTILITY(U,$J,358.3,19820,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19820,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,19820,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,19820,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,19821,0)
 ;;=C82.60^^86^994^53
 ;;^UTILITY(U,$J,358.3,19821,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19821,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,19821,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,19821,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,19822,0)
 ;;=D56.2^^86^994^54
 ;;^UTILITY(U,$J,358.3,19822,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19822,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,19822,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,19822,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,19823,0)
 ;;=D75.9^^86^994^55
 ;;^UTILITY(U,$J,358.3,19823,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19823,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,19823,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,19823,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,19824,0)
 ;;=D59.0^^86^994^58
 ;;^UTILITY(U,$J,358.3,19824,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19824,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,19824,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,19824,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,19825,0)
 ;;=D59.2^^86^994^59
 ;;^UTILITY(U,$J,358.3,19825,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19825,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,19825,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,19825,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,19826,0)
 ;;=R59.9^^86^994^62
 ;;^UTILITY(U,$J,358.3,19826,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19826,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,19826,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,19826,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,19827,0)
 ;;=D47.3^^86^994^63
